Track accepted paper

CiteScore: 4.75ℹ
CiteScore measures the average citations received per document published in this title. CiteScore values are based on citation counts in a given year (e.g. 2015) to documents published in three previous calendar years (e.g. 2012 – 14), divided by the number of documents in these three previous years (e.g. 2012 – 14).

Impact Factor: 4.581ℹImpact Factor:2016: 4.581The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

5-Year Impact Factor: 4.624ℹFive-Year Impact Factor:2016: 4.624To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

Source Normalized Impact per Paper (SNIP): 1.326ℹSource Normalized Impact per Paper (SNIP):2016: 1.326SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.

SCImago Journal Rank (SJR): 1.838ℹSCImago Journal Rank (SJR):2016: 1.838SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.

Author StatsℹAuthor Stats:Publishing your article with us has many benefits, such as having access to a personal dashboard: citation and usage data on your publications in one place. This free service is available to anyone who has published and whose publication is in Scopus.

Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced...

Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.

The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.

All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.

While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.

Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.

The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.

Original research submissions must contain:

A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways.

Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design.

It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.

Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.

Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .

This journal has partnered with Heliyon, an open access journal from Elsevier publishing quality peer reviewed research across all disciplines. Heliyon’s team of experts provides editorial excellence, fast publication, and high visibility for your paper. Authors can quickly and easily transfer their research from a Partner Journal to Heliyon without the need to edit, reformat or resubmit.
>Learn more at Heliyon.com